{"success":true,"data":{"pressRelease":{"id":"180980","rtpr_id":"nACSftK47a-20261027","ticker":"SGRY","exchange":"NASDAQ","all_tickers":["SGRY"],"title":"SGRY SHAREHOLDER BUYOUT INVESTIGATION: Kaskela Law is Investigating the Proposed Buyout of Surgery Partners, Inc. (SGRY) Shareholders at $23.50 Per Share - Fair Price or Insufficiently Low","author":"ACCESSWIRE","published_at":"2026-10-27T12:00:00.979Z","article_body":"PHILADELPHIA, PA / ACCESS Newswire (https://www.accessnewswire.com/) / October\n27, 2026 / Kaskela Law (https://pr.report/sriw) has launched an investigation\ninto the fairness of the proposed buyout of Surgery Partners, Inc.\n(NASDAQ:SGRY) shareholders to determine whether the proposed $23.50 per share\nbuyout price undervalues the company's shares.\n\nClick here for additional information:\nhttps://kaskelalaw.com/case/surgery-partners/\n\nOn October 26, 2026, Surgery Partners announced that it had agreed to be\nacquired by HealthSpan Partners at a price of $23.50 per share in cash.\nFollowing the closing of the proposed transaction, Surgery Partners'\nshareholders will be cashed out of their investment position and the company's\nshares will no longer be publicly traded.\n\nThe investigation seeks to determine whether Surgery Partners' investors will\nbe receiving sufficient financial consideration for their shares. Notably, at\nthe time the proposed transaction was announced, numerous stock analysts were\nmaintaining a price target in excess of $28.00 for Surgery Partners' shares.\n\nSurgery Partners shareholders who believe the buyout price is too low are\nencouraged to contact Kaskela Law (D. Seamus Kaskela, Esq. or Adrienne Bell,\nEsq.) for additional information about this investigation and their legal\nrights and options at (484) 229 - 0750. Alternatively, investors may contact\nthe firm via email at abell@kaskelalaw.com, or by clicking on the following\nlink (or if necessary, by copying and pasting the link into your browser):\n\nhttps://kaskelalaw.com/case/surgery-partners/\n\nABOUT KASKELA LAW:\n\nKaskela Law exclusively represents investors in securities fraud, corporate\ngovernance, and merger & acquisition litigation on a contingent basis (i.e.,\nthe firm's clients are never responsible for any out-of-pocket costs for legal\nrepresentation). Since 2020, the firm has helped to recover over $500 million\nfor investors. For additional information about Kaskela Law, including the\nfirm's recent notable recoveries for investors, please visit\nwww.kaskelalaw.com.\n\nKASKELA LAW LLC\nD. Seamus Kaskela, Esq.\nAdrienne Bell, Esq.\n1234 West Chester Pike, Suite 300\nWest Chester, PA 19382\n(484) 229 - 0750\nwww.kaskelalaw.com\n\nThis communication may constitute attorney advertising in certain\njurisdictions.\n\nSOURCE: Kaskela Law LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/sgry-shareholder-buyout-investigation-kaskela-law-is-investigati-1242161)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSftK47a-20261027","title":"SGRY SHAREHOLDER BUYOUT INVESTIGATION: Kaskela Law is Investigating the Proposed Buyout of Surgery Partners, Inc. (SGRY) Shareholders at $23.50 Per Share - Fair Price or Insufficiently Low","author":"ACCESSWIRE","ticker":"SGRY","created":"2026-10-27T12:00:00.979Z","tickers":["SGRY"],"exchange":"NASDAQ","article_body":"PHILADELPHIA, PA / ACCESS Newswire (https://www.accessnewswire.com/) / October\n27, 2026 / Kaskela Law (https://pr.report/sriw) has launched an investigation\ninto the fairness of the proposed buyout of Surgery Partners, Inc.\n(NASDAQ:SGRY) shareholders to determine whether the proposed $23.50 per share\nbuyout price undervalues the company's shares.\n\nClick here for additional information:\nhttps://kaskelalaw.com/case/surgery-partners/\n\nOn October 26, 2026, Surgery Partners announced that it had agreed to be\nacquired by HealthSpan Partners at a price of $23.50 per share in cash.\nFollowing the closing of the proposed transaction, Surgery Partners'\nshareholders will be cashed out of their investment position and the company's\nshares will no longer be publicly traded.\n\nThe investigation seeks to determine whether Surgery Partners' investors will\nbe receiving sufficient financial consideration for their shares. Notably, at\nthe time the proposed transaction was announced, numerous stock analysts were\nmaintaining a price target in excess of $28.00 for Surgery Partners' shares.\n\nSurgery Partners shareholders who believe the buyout price is too low are\nencouraged to contact Kaskela Law (D. Seamus Kaskela, Esq. or Adrienne Bell,\nEsq.) for additional information about this investigation and their legal\nrights and options at (484) 229 - 0750. Alternatively, investors may contact\nthe firm via email at abell@kaskelalaw.com, or by clicking on the following\nlink (or if necessary, by copying and pasting the link into your browser):\n\nhttps://kaskelalaw.com/case/surgery-partners/\n\nABOUT KASKELA LAW:\n\nKaskela Law exclusively represents investors in securities fraud, corporate\ngovernance, and merger & acquisition litigation on a contingent basis (i.e.,\nthe firm's clients are never responsible for any out-of-pocket costs for legal\nrepresentation). Since 2020, the firm has helped to recover over $500 million\nfor investors. For additional information about Kaskela Law, including the\nfirm's recent notable recoveries for investors, please visit\nwww.kaskelalaw.com.\n\nKASKELA LAW LLC\nD. Seamus Kaskela, Esq.\nAdrienne Bell, Esq.\n1234 West Chester Pike, Suite 300\nWest Chester, PA 19382\n(484) 229 - 0750\nwww.kaskelalaw.com\n\nThis communication may constitute attorney advertising in certain\njurisdictions.\n\nSOURCE: Kaskela Law LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/sgry-shareholder-buyout-investigation-kaskela-law-is-investigati-1242161)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-10-27T12:00:01.110251768Z","server_sent_at_ms":1793102401110},"received_at":"2026-10-27T12:00:01.176Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/sgry-shareholder-buyout-investigation-kaskela-law-is-investigati-1242161"},"analysis":{"id":"168806","press_release_id":"180980","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":["buyout price of $23.50 sits below analyst price targets of $28.00+ cited in the release"],"eventType":"legal_litigation","narrative":"Kaskela Law announced an investigation into whether the proposed $23.50-per-share cash buyout of Surgery Partners undervalues shareholders.\n\nSurgery Partners agreed on October 26, 2026 to be acquired by HealthSpan Partners, with shareholders cashed out and the stock delisted at closing.\n\nThe release notes some analysts maintained price targets above $28.00, but the document itself is a plaintiff-firm solicitation rather than an issuer disclosure or court action.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm buyout investigation solicitation -- suppress; watch issuer's own M&A filings instead."},"keyFigures":{"dealValueUsd":0,"customDimensions":{"buyout_price_per_share":23.5,"analyst_price_targets_mentioned":"$28.00+"}},"quotedText":"The investigation seeks to determine whether Surgery Partners' investors will be receiving sufficient financial consideration for their shares.","namedEntities":{"people":[{"name":"D. Seamus Kaskela","role":"attorney, Kaskela Law"},{"name":"Adrienne Bell","role":"attorney, Kaskela Law"}],"products":[],"companies":[{"name":"Surgery Partners, Inc.","ticker":"SGRY","relationship":"acquisition target / subject of investigation"},{"name":"HealthSpan Partners","relationship":"acquirer"},{"name":"Kaskela Law LLC","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$23.50 per share","context":"proposed buyout price for Surgery Partners shareholders"},{"amount":"$28.00","context":"analyst price targets exceeding the buyout price"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm buyout-fairness investigation solicitation issued by Kaskela Law under its own wire account. No court action, certified class, or settlement; the underlying acquisition was already disclosed by the issuer."},"tickerRelevance":{"others":[],"primary":"SGRY"},"globalImportance":18,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingMaNote":"real M&A event ($23.50/share by HealthSpan) was disclosed separately by issuer"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Kaskela Law announced an investigation into whether the proposed $23.50-per-share cash buyout of Surgery Partners undervalues shareholders.\n\nSurgery Partners agreed on October 26, 2026 to be acquired by HealthSpan Partners, with shareholders cashed out and the stock delisted at closing.\n\nThe release notes some analysts maintained price targets above $28.00, but the document itself is a plaintiff-firm solicitation rather than an issuer disclosure or court action.","key_figures":{"dealValueUsd":0,"customDimensions":{"buyout_price_per_share":23.5,"analyst_price_targets_mentioned":"$28.00+"}},"named_entities":{"people":[{"name":"D. Seamus Kaskela","role":"attorney, Kaskela Law"},{"name":"Adrienne Bell","role":"attorney, Kaskela Law"}],"products":[],"companies":[{"name":"Surgery Partners, Inc.","ticker":"SGRY","relationship":"acquisition target / subject of investigation"},{"name":"HealthSpan Partners","relationship":"acquirer"},{"name":"Kaskela Law LLC","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$23.50 per share","context":"proposed buyout price for Surgery Partners shareholders"},{"amount":"$28.00","context":"analyst price targets exceeding the buyout price"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-27T12:00:19.956Z","global_importance":18,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingMaNote":"real M&A event ($23.50/share by HealthSpan) was disclosed separately by issuer"}},"durationMs":5255,"modelName":"glm-5.3-flashx"}}